Trial Closures: OV18, IND218, MA28 and CE2

Wednesday, January 23, 2019

Trial Closure: OV18 (ICON6)

The lead group (MRC) has informed CCTG that the OV18 (ICON6): A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (with platinum-based chemotherapy) and Concurrent and Maintenance Cediranib in Women with Platinum-sensitive Relapsed Ovarian Cancer trial, is now been permanently closed/terminated.

Primary Publication:
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
JAMA Oncology. 2016 Jan;3(1):1066 -1074

The notification of permanent trial closure is posted on the CCTG website under the "Toolbox" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure/

Trial Closure: IND.218

The IND.218 trial has been formally permanently closed/terminated. No further ethics approvals or follow up data are required.

The IND.218 trial: A Study of Vinblastine and Temsirolimus in Pediatric Patients with Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours will be permanently closed/terminated as of tomorrow, 2019Jan16.

Primary publication:
Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218. Rebecca J. Deyell, Bing Wu, S.
Rod Rassekh, Dongsheng Tu, Yvan Samson, Adam Fleming, Eric Bouffet, Xiaoqun Sun, Jean Powers, Lesley Seymour, Sylvain Baruchel, Daniel A. Morgenstern

The notification of permanent trial closure is posted on the CCTG website under the "Toolbox" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure/

**Trial Closure: MA28 (NCCTG N9831)**

The MA28 (NCCTG N9831) trial has been formally permanently closed/terminated. No further ethics approvals or follow up data are required.

The notification of permanent trial closure is posted on the CCTG website under the “Toolbox” here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure/

MA28 (NCCTG N9831): Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment For Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer

Primary publication:


**Trial Closure: CE2 (RTOG 94-02)**

The CE2 trial has been formally permanently closed/terminated. No further ethics approvals or follow up data are required.

CE2 (RTOG 94-02): Phase III Intergroup Randomized Comparison of Radiation Alone versus Pre-radiation Chemotherapy For Pure and Mixed Anaplastic Oligodendrogliomas, has been permanently closed/terminated. This trial was activated in 1996Oct23 and closed to accrual 2002Mar29.

The notification of permanent trial closure is posted on the CCTG website under the "Toolbox" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure/